ArticleStem cells international2026
Adipose-Derived Mesenchymal Stem Cells Reduce miR-214-5p to Promote Ovarian Cancer Progression via the β-Catenin Pathway by Targeting PAX8.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adipose-Derived Mesenchymal Stem Cells Reduce miR-214-5p to Promote Ovarian Cancer Progression via the β-Catenin Pathway by Targeting PAX8.Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Building on our previous work, we found that human omental adipose-derived mesenchymal stem cells (ADSCs) promote ovarian cancer growth and metastasis by inducing PAX8, a key oncogenic transcription factor in ovarian cancer. TAZ is a core downstream effector of the Hippo signaling pathway, closely associated with malignant progression in multiple tumors, and our prior work confirmed that PAX8 can stabilize TAZ protein. In this study, we aimed to further clarify how ADSCs regulate PAX8 to explore the downstream signaling pathway driving malignant progression in ovarian cancer. Materials and Methods: Ovarian cancer cells were treated with ADSC-conditioned medium (ADSC-CM) to investigate the regulatory effect of ADSCs on miR-214-5p expression. qRT-PCR and western blot were applied to detect the levels of miR-214-5p, PAX8, β-catenin, and TAZ, so as to dissect the regulatory relationship of ADSCs/miR-214-5p/PAX8/β-catenin/TAZ. A dual-luciferase reporter assay verified the direct targeting interaction between miR-214-5p and PAX8. CCK-8 and Transwell invasion assays were conducted to assess the biological functions of the miR-214-5p/PAX8 axis in ovarian cancer progression. Results: We show that ADSC treatment significantly downregulated miR-214-5p in ovarian cancer cells. Moreover, PAX8 is a direct target of miR-214-5p: knockdown or overexpression of miR-214-5p altered PAX8 expression by directly binding to PAX8 mRNA. Additionally, PAX8 stabilizes TAZ by activating the β-catenin pathway. Functionally, miR-214-5p inhibited ovarian cancer cell proliferation and invasion by downregulating PAX8. Conclusion: Taken together, ADSCs downregulate miR-214-5p to increase PAX8 expression, which sequentially activates the β-catenin pathway and stabilizes TAZ. This novel signaling axis is responsible for ADSC-induced ovarian cancer growth and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.